EGFR and non-small cell lung carcinoma: Our study provided clinically relevant information about the baseline characteristics, survival outcomes and patterns of treatment failure of a relatively large number of metastatic NSCLC patients treated with first-line EGFR-TKIs and harboring various types of EGFR mutations.